| URL | https://news.cuanschutz.edu/news-stories/cell-and- |
| Source | news.cuanschutz.edu |
| Date Published | 08/13/2021 |
| Mentions specific company case(s) of reshoring, kept from offshoring, or transplant | Yes |
| Company/Division name | Bioscience 5 |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2021 |
| Year reshoring implemented or to be implemented: | 2022 |
| Domestically, the work will be done: | In-house |
| City reshored to: | Aurora |
| State(s) reshored to: | CO |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | cell and gene therapy |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Manufacturing/engineering joint innovation (R&D) |